Holen Sie sich die Stockscreener-App
3.93
1.29%
0.05
Handel nachbörslich:
3.93
Schlusskurs vom Vortag:
$3.88
Offen:
$3.89
24-Stunden-Volumen:
806.53K
Relative Volume:
1.30
Marktkapitalisierung:
$314.93M
Einnahmen:
$70.14M
Nettoeinkommen (Verlust:
$-76.24M
KGV:
-4.6235
EPS:
-0.85
Netto-Cashflow:
$-57.06M
1W Leistung:
-3.20%
1M Leistung:
+15.25%
6M Leistung:
+8.86%
1J Leistung:
+92.65%
1-Tages-Spanne:
$3.715
$4.1485
1-Wochen-Bereich:
$3.70
$4.20
52-Wochen-Spanne:
$1.85
$4.91
Codexis Inc Stock (CDXS) Company Profile
Firmenname
Codexis Inc
Sektor
Branche
Telefon
650-421-8100
Adresse
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Vergleichen Sie CDXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CDXS | 3.93 | 314.93M | 70.14M | -76.24M | -57.06M | -0.85 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2021-04-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-01 | Eingeleitet | Stifel | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-10 | Eingeleitet | The Benchmark Company | Buy |
| 2019-01-17 | Hochstufung | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | Eingeleitet | Stephens | Overweight |
| 2017-10-13 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-31 | Eingeleitet | Jefferies | Buy |
| 2017-01-26 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Codexis Inc Aktie (CDXS) Neueste Nachrichten
Codexis (NASDAQ:CDXS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics - GlobeNewswire
Codexis Achieves 98% Efficiency in Breakthrough siRNA Synthesis Platform | CDXS Stock News - StockTitan
Baillie Gifford & Co. Sells 895,002 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis adds biotech veteran Raymond De Vré to board - Investing.com India
Codexis Strengthens Board and Updates Bylaws - TipRanks
CDXSCodexis, Inc. Latest Stock News & Market Updates - StockTitan
Codexis adds biotech veteran Raymond De Vré to board By Investing.com - Investing.com UK
Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors - GlobeNewswire
Codexis Strengthens Board with Biotech Veteran Raymond De Vré, Former PolyPeptide CEO | CDXS Stock News - StockTitan
Biofuel Enzymes Market Growth Surge: Key Players and Market - openPR
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics - GlobeNewswire
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for - The Bakersfield Californian
Codexis to Showcase Breakthrough RNA Platform, Partners with Bachem at TIDES Europe 2024 | CDXS Stock News - StockTitan
Codexis Announces New Employment Inducement Grants - The Manila Times
Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors - Simply Wall St
Benchmark Downgrades Codexis (CDXS) - MSN
CDXS (Codexis) PE Ratio : At Loss (As of Nov. 06, 2024) - GuruFocus.com
Codexis (FRA:4QK) 3-Year EBITDA Growth Rate : -26.40% (As of Sep. 2024) - GuruFocus.com
Benchmark Reaffirms “Hold” Rating for Codexis (NASDAQ:CDXS) - Defense World
Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock By Investing.com - Investing.com Australia
abrdn plc Grows Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock - Investing.com India
Codexis to Participate in Upcoming Healthcare Conferences - The Manila Times
Codexis (NASDAQ:CDXS) Earns Hold Rating from Benchmark - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$7.17 - Yahoo Finance
Codexis, Inc. Announces Strong Third Quarter 2024 Financial Results - Defense World
Codexis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Codexis, Inc. (NASDAQ:CDXS) Q3 2024 Earnings Call Transcript - Insider Monkey
Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Earnings call: Codexis reports revenue growth and strategic focus in Q3 2024 - Investing.com
Codexis Inc Q3 2024 Earnings: Revenue Hits $12.83M, Beating Esti - GuruFocus.com
Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ... - Yahoo Finance
Codexis Reports Strong Q3 Revenue Growth - TipRanks
Codexis: Q3 Earnings Snapshot - CT Insider
Codexis Reports Third Quarter 2024 Financial Results - The Manila Times
Assenagon Asset Management S.A. Increases Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Short Interest Update - MarketBeat
Opaleye management buys $72,720 in Codexis stock By Investing.com - Investing.com Canada
Finanzdaten der Codexis Inc-Aktie (CDXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):